Metformin Blood Test Monitoring: What to Watch

Metformin is the most widely prescribed diabetes medication in the world, and in the UK alone, more than 4 million people take it daily. Originally developed for type 2 diabetes, it is now prescribed for polycystic ovary syndrome (PCOS), and increasingly used off-label by the longevity community following promising research on ageing. Regardless of why you take it, regular blood test monitoring is essential — not just to check whether it is working, but to catch the side effects it can quietly cause.

How metformin works

Metformin primarily reduces hepatic glucose output (the liver's production of sugar) and improves insulin sensitivity in peripheral tissues. It does not stimulate insulin secretion, which is why it rarely causes hypoglycaemia on its own. At standard doses of 500–2,000 mg daily, it typically reduces HbA1c by 10–15 mmol/mol — a clinically significant improvement.

But metformin is not metabolically inert. It affects vitamin B12 absorption, alters kidney function thresholds, and requires hepatic processing. Monitoring these pathways is what separates safe long-term use from preventable complications.

The critical markers to monitor

HbA1c — is metformin actually working?

The primary reason most people take metformin is to lower blood sugar, and HbA1c is the definitive measure of glycaemic control over the preceding 2–3 months. Target levels depend on individual circumstances:

• Type 2 diabetes (monotherapy): Target HbA1c of 48 mmol/mol (6.5%) or below, per NICE guideline NG28.
• Type 2 diabetes (combination therapy): Target of 53 mmol/mol (7.0%) or below.
• Pre-diabetes/prevention: Below 42 mmol/mol (6.0%).
• PCOS: Targets vary, but maintaining HbA1c below 42 mmol/mol indicates good insulin sensitivity.

If HbA1c is not dropping after 3–6 months on metformin, the dose may need increasing, adherence may be inconsistent (often due to GI side effects — switching to slow-release can help), or additional medication may be required. Without testing, you are guessing whether the drug is doing its job.

Vitamin B12 — the hidden depletion

This is the most under-monitored consequence of metformin use. The MHRA issued updated guidance in 2022 recommending annual B12 monitoring for all patients on long-term metformin, following evidence that up to 30% of long-term users develop B12 deficiency.

The mechanism is well-established: metformin interferes with B12 absorption in the terminal ileum by disrupting the calcium-dependent uptake process. The depletion is gradual — it can take 5–10 years to become clinically significant — which is exactly why it is so often missed. By the time symptoms appear (fatigue, numbness, tingling, memory problems, balance issues), nerve damage may be partially irreversible.

The correct marker is Active B12 (holotranscobalamin), not total B12. Total B12 includes inactive forms and can appear normal while functional B12 is deficient. Active B12 below 25.1 pmol/L is deficient; 25.1–37 pmol/L is the grey zone where symptoms often begin. If Active B12 is borderline, methylmalonic acid (MMA) confirms functional deficiency.

All metformin users should supplement B12 (at least 1,000 µg daily of methylcobalamin or cyanocobalamin) and test annually to verify absorption.

Kidney function — eGFR and creatinine

Metformin is renally excreted — the kidneys clear it from the body unchanged. If kidney function declines, metformin accumulates, raising the risk of lactic acidosis — a rare but potentially fatal complication. Current UK guidelines state:

• eGFR above 60 mL/min: Standard dosing, no adjustment needed.
• eGFR 30–60 mL/min: Dose reduction required. Review frequency increases to every 3–6 months.
• eGFR below 30 mL/min: Metformin must be stopped entirely.

Kidney function naturally declines with age — approximately 1 mL/min/year after 40. This means someone who starts metformin at 50 with an eGFR of 75 may cross the dose-reduction threshold within 15 years without any acute kidney disease. Regular monitoring catches this gradual decline before it becomes dangerous.

Creatinine, urea and electrolytes should be checked alongside eGFR for a complete renal picture.

Liver function

Although metformin is not hepatotoxic in the way isotretinoin is, it is processed through the liver and the conditions it treats (type 2 diabetes, PCOS, metabolic syndrome) are strongly associated with non-alcoholic fatty liver disease (NAFLD). An estimated 70% of people with type 2 diabetes have some degree of NAFLD.

Monitoring ALT, AST, GGT and ALP serves a dual purpose: confirming that metformin is not causing hepatic stress and screening for the fatty liver disease that commonly coexists with the conditions metformin treats. ALT above 35 U/L (women) or 41 U/L (men) warrants further investigation.

Full blood count (FBC)

B12 deficiency causes macrocytic anaemia — characterised by abnormally large red blood cells (high MCV, typically above 100 fL) and potentially low haemoglobin. An FBC can flag this before B12 is even tested, making it a useful screening tool. If MCV is rising on serial blood tests, B12 deficiency should be considered immediately in anyone on metformin.

An FBC also monitors for any unexpected haematological changes and provides baseline values for comparison over time.

Folate

Folate and B12 metabolism are intertwined. Folate deficiency can mask B12 deficiency (and vice versa) because both cause macrocytic anaemia. Checking folate alongside Active B12 ensures that neither deficiency is hidden behind the other. Serum folate above 3.9 µg/L is generally adequate; below 3.0 µg/L is deficient.

Monitoring schedule for metformin users

• Baseline (before starting or at first opportunity): HbA1c, Active B12, kidney function (eGFR, creatinine), liver function, FBC, folate.
• 3 months: HbA1c to assess initial response. Kidney function if eGFR was below 60 at baseline.
• 6 months: HbA1c, kidney function.
• 12 months and annually thereafter: Full panel — HbA1c, Active B12, kidney function, liver function, FBC, folate. This is the MHRA-recommended minimum for long-term users.

If you have been on metformin for years without B12 monitoring, do not wait for your next annual check. Test now. The longer the gap, the greater the risk of undetected depletion.

Recommended Lola Health tests

• Core Health 45 — £120 — The most efficient single panel for metformin monitoring: includes HbA1c, Active B12, folate, full liver function, kidney function (eGFR, creatinine, urea), full blood count, vitamin D, iron studies and thyroid markers. One test covers every marker a metformin user needs to track, with the added benefit of catching related conditions (thyroid dysfunction is common in type 2 diabetes; iron deficiency can coexist with B12 depletion).
• Blood Health 6 — £89 — Focused on the highest-risk deficiency: Active B12, ferritin, iron, folate, transferrin saturation and full blood count. If you are specifically concerned about B12 depletion from metformin and want a targeted, affordable check, this covers the essentials.

Special considerations

PCOS patients on metformin

Women with PCOS who take metformin should also monitor testosterone, SHBG and fasting insulin alongside the standard panel. Metformin improves insulin sensitivity in PCOS, which in turn lowers androgen levels — but the degree of improvement varies. Blood tests confirm whether the hormonal picture is actually improving or whether additional treatment is needed.

Longevity/off-label users

The growing community using metformin for anti-ageing purposes (inspired by the TAME trial and observational data suggesting reduced all-cause mortality in diabetic metformin users) still needs the same monitoring. Lower doses (500–1,000 mg daily) carry lower risk, but B12 depletion and kidney function decline are dose-independent over time. If you are taking metformin without a prescription or clinical oversight, regular blood testing is not optional — it is the minimum safeguard.

Drug interactions

Certain medications increase the risk of metformin-related complications. ACE inhibitors, ARBs and NSAIDs can all impair kidney function, accelerating the decline in eGFR that determines metformin safety. Proton pump inhibitors (omeprazole, lansoprazole) further reduce B12 absorption, compounding metformin's own B12-depleting effect. If you take any of these alongside metformin, more frequent monitoring is warranted.

The bottom line

Metformin is a remarkably effective and generally safe medication, but "generally safe" assumes proper monitoring. The three non-negotiable checks are HbA1c (is it working?), Active B12 (is it depleting your stores?) and kidney function (can your body still clear it safely?). Add liver function, FBC and folate for a complete picture. Annual testing is the minimum; more frequent monitoring if you are newly started, have impaired kidney function, or take interacting medications. The cost of an annual blood test is trivial compared with the cost of undetected B12 neuropathy or metformin accumulation from declining kidney function.